Mehmet Sofuoglu, MD, PhD

Our research is focused on development of novel treatments for substance use disorders and comorbid psychiatric disorders. We conduct both Phase 1 human laboratory studies and outpatient clinical trials testing the efficacy of potential treatments. We are also interested in tobacco regulatory science with a focus on the impact of nicotine and flavors on the appeal and abuse potential of tobacco products. We have developed a novel intravenous nicotine self-administration model which allows examination of both rewarding and aversive effects of nicotine in male and female smokers.
Recent projects include:

• The reinforcing threshold for intravenous nicotine self-administration in male and female smokers.
• Individual factors influencing the rewarding effects of nicotine in male and female smokers.
• Impact of menthol and other flavors on the rewarding effects of nicotine in humans.
• The potential efficacy of cognitive enhancers as a treatment for substance use disorders.
• Progesterone as a potential treatment to prevent relapse in women with substance use disorder.